General Information of the Drug (ID: M6APDG04211)
Name
Anti-IP10
Status
Phase 2
TTD Drug ID
D0L7LH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
C-X-C motif chemokine 10 (CXCL10)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for Anti-IP10. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Anti-IP10 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for Anti-IP10. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-IP10 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). [1], [2]
References
Ref 1 m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020 Oct 15;39(20):e104514. doi: 10.15252/embj.2020104514. Epub 2020 Sep 23.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)